Login to Your Account



Pharma: Other News To Note


Friday, February 15, 2013
• Eisai Inc., of Woodcliff Lake, N.J., said the FDA granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription